Text Size

Effects of Stress-reducing Aromatherapy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Barry S. Oken, Oregon Health and Science University
ClinicalTrials.gov Identifier:
NCT01307748
First received: March 2, 2011
Last updated: March 18, 2013
Last verified: March 2013
History of Changes

March 2, 2011
March 18, 2013
December 2010
December 2012   (final data collection date for primary outcome measure)
  • Salivary cortisol change [ Time Frame: assessed at baseline, challenge tasks, post-challenge ] [ Designated as safety issue: No ]
    Change in salivary cortisol
  • EEG frontal lateral asymmetry change [ Time Frame: at baseline, challenge tasks, post-challenge ] [ Designated as safety issue: No ]
    Change in frontal lateral asymmetry
Same as current
Complete list of historical versions of study NCT01307748 on ClinicalTrials.gov Archive Site
Cognitive performance change [ Time Frame: at baseline and post-challenge ] [ Designated as safety issue: No ]
change in cognitive performance
Same as current
Not Provided
Not Provided
 
Effects of Stress-reducing Aromatherapy
Physiologic and Expectancy Effects of Stress-reducing Aroma in Older Adults

The study purpose is to evaluate efficacy of stress-reducing aromatherapy and learn about how aromatherapy works.

The study purpose is to evaluate efficacy of stress-reducing aromatherapy and learn about how aromatherapy works by comparing participants' physiologic responses to laboratory challenge tasks with and without experiencing aromatherapy.
Interventional
Phase 2
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Prevention
Stress-related Problems
Other: aroma
Comparison of known stress reducing aroma to placebo aromas without stress-reducing effects
Other Names:
  • lavandula angustifolia
  • cocos nucifera
  • aqua destillata
  • Experimental: stress reducing aroma
    aroma with reported stress reducing effects
    Intervention: Other: aroma
  • Placebo Comparator: Placebo aroma 1
    Intervention: Other: aroma
  • Placebo Comparator: Placebo aroma 2
    Intervention: Other: aroma
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
92
December 2012
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • in good physical and cognitive health
  • reporting moderate level of stress
  • able to perceive aromas
  • able to understand and follow study instructions

Exclusion Criteria:

  • taking medications affecting CNS function or physiologic measures (e.g. steroids or neuroleptics)
  • reporting smell sensitivities or allergies
  • smoking presently or in the past less than one year prior to enrollment
Both
50 Years to 85 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01307748
IRB#00006890
Yes
Barry S. Oken, Oregon Health and Science University
Oregon Health and Science University
Not Provided
Principal Investigator: Barry S Oken, MD Oregon Health and Science University
Oregon Health and Science University
March 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP